ImmunoGen (IMGN) Reports Q3 Loss, Misses Revenue Estimates Posted byZacks Equity Research October 29, 2021 Leave a comment on ImmunoGen (IMGN) Reports Q3 Loss, Misses Revenue Estimates ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.26% and -53.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?